• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Biomarker Partnering Terms and Agreements Product Image

Biomarker Partnering Terms and Agreements

  • ID: 1518944
  • November 2014
  • Region: Global
  • 1048 Pages
  • CurrentPartnering

FEATURED COMPANIES

  • Abbott
  • Bayer
  • Bristol-Myers Squibb
  • Eisai
  • Johnson & Johnson
  • Merck & Co
  • MORE

The Biomarker Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the biomarker partnering deals and agreements entered into by the worlds leading healthcare companies.

Trends in biomarker partnering deals
Biomarker partnering agreement structure
Biomarker partnering contract documents
Top biomarker deals by value
Most active biomarker dealmakers

The Biomarker Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the biomarker partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter biomarker partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors biomarker technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of READ MORE >

Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Abbott
  • Bayer
  • Bristol-Myers Squibb
  • Eisai
  • Johnson & Johnson
  • Merck & Co
  • MORE

Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in biomarker dealmaking

2.1. Introduction
2.2. Biomarker partnering over the years
2.3. Big pharma biomarker dealmaking activity
2.4. Most active biomarker dealmakers
2.5. Biomarker partnering by deal type
2.6. Biomarker partnering by disease type
2.7 Average deal terms for biomarkers
2.7.1 Biomarker headline values
2.7.2 Biomarker upfront payments
2.7.3 Biomarker milestone payments
2.7.4 Biomarker royalty rates
2.8. The anatomy of biomarker partnering
2.8.1 The anatomy of a biomarker deal
2.8.1.a Case study 1: Kinemed, GlaxoSmithKline- June 2012
2.8.1.b Case study 2: TrovaGene, Columbia University- December 2011

Chapter 3 – Leading biomarker deals

3.1. Introduction
3.2. Top biomarker deals by value

Chapter 4 – Big pharma biomarker deals

4.1. Introduction
4.2. How to use big pharma biomarker partnering deals
4.3. Big pharma biomarker partnering company profiles
Abbott
Amgen
AstraZeneca
Bayer
Biogen Idec
Boehringer Ingelheim
Bristol-Myers Squibb
Celgene
Daiichi Sankyo
Eisai
Eli Lilly
GlaxoSmithKline
Johnson & Johnson
Kyowa Hakko Kirin
Lundbeck
Merck & Co
Merck KGaA
Novartis
Novo Nordisk
Otsuka
Pfizer
Purdue
Roche
Sanofi
Servier
Takeda
Teva

Chapter 5 – Biomarker contracts dealmaking directory

5.1. Introduction
5.2. Biomarker deals with contract by company A-Z
5.3. Biomarker deals with contract by deal type
5.4. Biomarker deals with contract by therapy area
Chapter 6 – Biomarker dealmaking by technology type

6.1. Introduction
6.2. Deals by biomarker type
Biomarkers

Chapter 7 – Biomarker partnering resource center

7.1. Online biomarker partnering
7.2. Biomarker partnering events
7.3. Further reading on biomarker dealmaking

Appendices

Appendix 1 – Biomarker partnering by company A-Z
Appendix 2 - Biomarker partnering by stage of development
Appendix 3 - Biomarker partnering by deal type
Appendix 4 - Biomarker partnering by therapy area

Table of figures

Figure 1: Biomarker partnering since 2009
Figure 2: Big pharma – top 50 – biomarker deals 2009 to 2014
Figure 3: Big pharma biomarker deal frequency – 2009 to 2014
Figure 4: Active biomarker dealmaking activity– 2009 to 2014
Figure 5: Biomarker partnering by deal type since 2009
Figure 6: Biomarker partnering by disease type since 2009
Figure 7: Biomarker partnering by oncology target since 2009
Figure 8: Biomarker deals with a headline value by year- 2014
Figure 9: Biomarker deals with a headline value by year- 2013
Figure 10: Biomarker deals with a headline value by year- 2012
Figure 11: Biomarker deals with a headline value by year- 2011
Figure 12: Biomarker deals with a headline value by year- 2010
Figure 13: Biomarker deals with a headline value by year- 2009
Figure 14: Summary median headline value by year, 2009-2014
Figure 15: Biomarker deals with an upfront value by year- 2014
Figure 16: Biomarker deals with an upfront value by year- 2013
Figure 17: Biomarker deals with an upfront value by year- 2012
Figure 18: Biomarker deals with an upfront value by year- 2011
Figure 19: Biomarker deals with an upfront value by year- 2010
Figure 20: Biomarker deals with an upfront value by year- 2009
Figure 21: Summary median upfront value by year, 2009-2014
Figure 22: Biomarker deals with a milestone value by year- 2014
Figure 23: Biomarker deals with a milestone value by year- 2013
Figure 24: Biomarker deals with a milestone value by year- 2012
Figure 25: Biomarker deals with a milestone value by year- 2011
Figure 26: Biomarker deals with a milestone value by year- 2010
Figure 27: Biomarker deals with a milestone value by year- 2009
Figure 28: Biomarker deals with a royalty rate by year- 2014
Figure 29: Biomarker deals with a royalty rate by year- 2013
Figure 30: Biomarker deals with a royalty rate by year- 2012
Figure 31: Biomarker deals with a royalty rate by year- 2011
Figure 32: Biomarker deals with a royalty rate by year- 2010
Figure 33: Biomarker deals with a royalty rate by year- 2009
Figure 34: Summary median royalty rate by year, 2009-2014
Figure 35: Components of the typical biomarker deal structure
Figure 36: Top biomarker deals by value since 2009
Figure 37: Online partnering resources
Figure 38: Forthcoming partnering events

Note: Product cover images may vary from those shown

Abbott
Amgen
AstraZeneca
Bayer
Biogen Idec
Boehringer Ingelheim
Bristol-Myers Squibb
Celgene
Daiichi Sankyo
Eisai
Eli Lilly
GlaxoSmithKline
Johnson & Johnson
Kyowa Hakko Kirin
Lundbeck
Merck & Co
Merck KGaA
Novartis
Novo Nordisk
Otsuka
Pfizer
Purdue
Roche

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos